{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T11:01:11Z","timestamp":1780657271685,"version":"3.54.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.annonc.2020.04.008","type":"journal-article","created":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T14:08:00Z","timestamp":1587996480000},"page":"991-1000","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients"],"prefix":"10.1016","volume":"31","author":[{"given":"D.S.","family":"Ross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Schram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Razavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.M.","family":"Lagana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Scaltriti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.F.","family":"Bromberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ladanyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.M.","family":"Hyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Drilon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Zehir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Benayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Chandarlapaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.F.","family":"Hechtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.annonc.2020.04.008_bib1","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/ng.2822","article-title":"ESR1 ligand-binding domain mutations in hormone-resistant breast cancer","volume":"45","author":"Toy","year":"2013","journal-title":"Nat Genet"},{"issue":"12","key":"10.1016\/j.annonc.2020.04.008_bib2","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/ng.2823","article-title":"Activating ESR1 mutations in hormone-resistant metastatic breast cancer","volume":"45","author":"Robinson","year":"2013","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.annonc.2020.04.008_bib3","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1158\/2159-8290.CD-15-1523","article-title":"Activating ESR1 mutations differentially affect the efficacy of ER antagonists","volume":"7","author":"Toy","year":"2017","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.annonc.2020.04.008_bib4","doi-asserted-by":"crossref","first-page":"8728","DOI":"10.1093\/annonc\/mdy025","article-title":"Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer","volume":"29","author":"Hartmaier","year":"2018","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2020.04.008_bib5","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","article-title":"The genomic landscape of endocrine-resistant advanced breast cancers","volume":"34","author":"Razavi","year":"2018","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.annonc.2020.04.008_bib6","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1158\/2159-8290.CD-17-0535","article-title":"Expressed gene fusions as frequent drivers of poor outcomes in hormone receptor-positive breast cancer","volume":"8","author":"Matissek","year":"2018","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.annonc.2020.04.008_bib7","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology","volume":"17","author":"Cheng","year":"2015","journal-title":"J\u00a0Mol Diagn"},{"issue":"5","key":"10.1016\/j.annonc.2020.04.008_bib8","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41379-018-0175-7","article-title":"Diagnosis of known sarcoma fusions and novel fusion partners by targeted RNA sequencing with identification of a recurrent ACTB-FOSB fusion in pseudomyogenic hemangioendothelioma","volume":"32","author":"Zhu","year":"2019","journal-title":"Mod Pathol"},{"issue":"12","key":"10.1016\/j.annonc.2020.04.008_bib9","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/nm.3729","article-title":"Anchored multiplex PCR for targeted next-generation sequencing","volume":"20","author":"Zheng","year":"2014","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.annonc.2020.04.008_bib10","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1158\/0008-5472.CAN-18-3126","article-title":"Colorectal carcinomas containing hypermethylated MLH1 promoter and wild-type BRAF\/KRAS are enriched for targetable kinase fusions","volume":"79","author":"Cocco","year":"2019","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.annonc.2020.04.008_bib11","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S1535-6108(02)00180-0","article-title":"Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma","volume":"2","author":"Tognon","year":"2002","journal-title":"Cancer Cell"},{"issue":"16","key":"10.1016\/j.annonc.2020.04.008_bib12","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer","volume":"28","author":"Hammond","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"10.1016\/j.annonc.2020.04.008_bib13","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2020.04.008_bib14","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1097\/PAS.0000000000000911","article-title":"Pan-Trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions","volume":"41","author":"Hechtman","year":"2017","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.annonc.2020.04.008_bib15","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","article-title":"Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma","volume":"36","author":"Javle","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2020.04.008_bib16","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","article-title":"Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma","volume":"7","author":"Goyal","year":"2017","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.annonc.2020.04.008_bib17","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1038\/s41467-018-07341-4","article-title":"RET rearrangements are actionable alterations in breast cancer","volume":"9","author":"Paratala","year":"2018","journal-title":"Nat Commun"},{"issue":"13","key":"10.1016\/j.annonc.2020.04.008_bib18","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1158\/1078-0432.CCR-17-2961","article-title":"Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance","volume":"24","author":"Yu","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.annonc.2020.04.008_bib19","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1158\/2159-8290.CD-16-0795","article-title":"A\u00a0phase Ib dose-escalation study of encorafenib and cetuximab with or without alpelisib in metastatic BRAF-mutant colorectal cancer","volume":"7","author":"van Geel","year":"2017","journal-title":"Cancer Discov"},{"issue":"21","key":"10.1016\/j.annonc.2020.04.008_bib20","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1200\/JCO.2011.37.2482","article-title":"Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression","volume":"30","author":"Lindstrom","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2020.04.008_bib21","first-page":"1557","article-title":"Changes in estrogen receptor, progesterone receptor and Her-2\/neu status with time: discordance rates between primary and metastatic breast cancer","volume":"29","author":"Broom","year":"2009","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.annonc.2020.04.008_bib22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10549-004-2756-z","article-title":"Impact of metastatic estrogen receptor and progesterone receptor status on survival","volume":"90","author":"Lower","year":"2005","journal-title":"Breast Cancer Res Treat"},{"issue":"24","key":"10.1016\/j.annonc.2020.04.008_bib23","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1200\/JCO.2015.61.1459","article-title":"Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology Clinical Practice Guideline","volume":"33","author":"Van Poznak","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl_3","key":"10.1016\/j.annonc.2020.04.008_bib24","first-page":"iii47","article-title":"First report of AURORA, the breast international group (BIG) molecular screening initiative for metastatic breast cancer (mbc) patients (pts)","volume":"30","author":"Aftimos","year":"2019","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2020.04.008_bib25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/annonc\/mdz036","article-title":"Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"30","author":"Condorelli","year":"2019","journal-title":"Ann Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420393066?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420393066?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T05:58:39Z","timestamp":1760335119000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753420393066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0923753420393066"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2020.04.008","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2020.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Society for Medical Oncology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}